Wuhan Humanwell Innovative Drug Research and Development Center

Wuhan Humanwell Innovative Drug Research and Development Center is the primary research and development subsidiary of Humanwell Healthcare Group, a major Chinese pharmaceutical company. Located in Wuhan's East Lake High-tech Development Zone, the center specializes in the discovery and clinical development of novel small molecules and biologics. Its core therapeutic focus lies in anesthesiology, analgesia, and central nervous system (CNS) disorders, where it has established a leading market position in China. The center's most notable achievement is the development of remimazolam tosylate, a novel sedative-hypnotic agent that has successfully reached commercialization. Beyond CNS, the center is actively expanding its pipeline into oncology and immunology with several candidates in clinical trials. It operates as a comprehensive drug discovery platform, integrating medicinal chemistry, pharmacology, and translational medicine to advance its therapeutic candidates.